Multi-centric study to contain antimicrobial resistant neonatal sepsis begins in India
An international clinical trial named NeoSep1 has expanded to India to test new antibiotic combinations for treating neonatal sepsis. The study aims to address the growing threat of antimicrobial resistance in newborns across Asia and Africa.
Why it matters
Neonatal sepsis is a leading cause of infant mortality, and finding effective antibiotic treatments is critical as existing drugs become increasingly ineffective against resistant infections.
Striking at the heart of antimicrobial resistance, the international NeoSep 1 trial to evaluate life-saving antibiotic combinations for newborns with sepsis has expanded to India, with the first baby being recruited at the Jawaharlal Postgraduate Education Institute of Medical and Research (JIPMER) in Puducherry.
The article provides a straightforward, objective report on a medical study and its public health implications.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in